dc.contributor.author | Pedersen, Elena Didenko | |
dc.contributor.author | Stenager, Egon | |
dc.contributor.author | Vadgaard, J. L. | |
dc.contributor.author | Jensen, Michael Broksgaard | |
dc.contributor.author | Schmid, Roman | |
dc.contributor.author | Meland, Nils | |
dc.contributor.author | Magnussen, Gry Irene | |
dc.contributor.author | Frederiksen, Jette Lautrup | |
dc.date.accessioned | 2019-07-26T08:34:47Z | |
dc.date.available | 2019-07-26T08:34:47Z | |
dc.date.issued | 2018-04-19 | |
dc.identifier.citation | Pedersen, E. D., Stenager, E., Vadgaard, J. L., Jensen, M. B., Schmid, R., Meland, N., ... & Frederiksen, J. L. (2018). Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label scandinavian noninterventional study (the scansmart study). Patient preference and adherence, 12, 569. | en |
dc.identifier.issn | 1177-889X | |
dc.identifier.uri | https://hdl.handle.net/10642/7370 | |
dc.description.abstract | Background: Disease modifying drugs help control the course of relapsing remitting multiple sclerosis (RRMS); however, good adherence is needed for long-term outcomes.
Objective: To evaluate patient adherence to treatment with subcutaneous interferon beta-1a using RebiSmart® and assess injection-site reactions and treatment satisfaction.
Methods: This prospective, single-arm, open-label, noninterventional multicenter Phase IV trial included disease modifying drug-experienced mobile patients with RRMS. Adherence was measured over 12 weeks. Items 13–23, 35, 37, and 38 of the Multiple Sclerosis Treatment Concerns Questionnaire (injection-site reactions and treatment satisfaction) were recorded at 12 weeks.
Results: Sixty patients were recruited (mean age 43.7 [±SD 7.9] years; 83% female; mean years since multiple sclerosis diagnosis 6.7 [SD 4.5]). Adherence data were obtained in 54 patients only due to technical problems with six devices. Over 12 weeks, 89% (n=48) of patients had ≥90% adherence to treatment. Most patients experienced mild influenza-like symptoms and injection-site reactions, and global side effects were minimal. Most patients (78%) rated the convenience as the most important aspect of the device, and most experienced no or mild pain.
Conclusion: RRMS patients treated with subcutaneous interferon beta-1a, administered with RebiSmart, demonstrated generally good adherence, and the treatment was generally well tolerated. | en |
dc.language.iso | en | en |
dc.publisher | Dove Medical Press | en |
dc.relation.ispartofseries | Patient preference and adherence;12 | |
dc.rights | Attribution-NonCommercial 3.0 United States
This is an open access article, originally published at https://doi.org/10.2147/PPA.S154417 | en |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/us/ | * |
dc.subject | Artikkel | en |
dc.subject | VDP::Medisinske Fag: 700 | en |
dc.title | Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label scandinavian noninterventional study (The scansmart study) | en |
dc.type | Journal article | en |
dc.type | Peer reviewed | en |
dc.description.version | publishedVersion | en |
dc.identifier.doi | https://doi.org/10.2147/PPA.S154417 | |
dc.identifier.cristin | 1606722 | |